LEIDOS BIOMEDICAL RESEARCH, INC.
DEVELOP, QUALIFY IMMUNOLOGICAL ASSAYS, AND PROVIDE CLINICAL SAMPLE TESTING FOR AAV-BASED GENE THERAPY CLINICAL CANDIDATES
DEVELOP, QUALIFY IMMUNOLOGICAL ASSAYS, AND PROVIDE CLINICAL SAMPLE TESTING FOR AAV-BASED GENE THERAPY CLINICAL CANDIDATES is a funding opportunity from LEIDOS BIOMEDICAL RESEARCH, INC., up to 2510508, closing September 14, 2030.
Sep 14, 2030
(1506d left)Overview
The contractor shall develop OR adapt/use previously developed (if available): anti-drug antibody (ADA) and neutralizing antibody (NAb) assays as well as T-cell immunogenicity assays to support NACTS clinical trials including the MMA-101 gene therapy candidate and implement the assays for testing of clinical samples…